This is the most important thing to understand
The quick answer for busy clinicians If a colleague asks semaglutide or phentermine? in a hallway, the honest one-sentence version is this: reach for semaglutide when you are treating obesity as a chronic disease that needs durable, year-over-year management, and reach for phentermine when you want an inexpensive, fast short-term jump-start for a motivated patient who does not need or cannot afford long-term pharmacotherapy
However, with IBD-current biologic therapies, all these mean some patients primary non-responders, experience a loss of response, intolerance or side effects, defining the urgent unmet need for novel treatments (13, 14)
The KDIGO (Kidney Disease: Improving Global Outcomes) guidelines are currently being revised, and Im not privy to those discussions, but I would think that its quite likely that this will become one of the major pillars of standard of care for the prevention of chronic kidney disease, Drucker said
Compounded preparations are not subject to the same regulatory oversight as FDA-approved medications
